These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 15695404

  • 21. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Ee PL, He X, Ross DD, Beck WT.
    Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
    [Abstract] [Full Text] [Related]

  • 22. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M.
    Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
    [Abstract] [Full Text] [Related]

  • 23. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE, Madsen MW, Briand P.
    Cancer Res; 1994 Mar 15; 54(6):1587-95. PubMed ID: 8137264
    [Abstract] [Full Text] [Related]

  • 24. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q.
    Cancer Chemother Pharmacol; 2006 Sep 15; 58(3):374-83. PubMed ID: 16404634
    [Abstract] [Full Text] [Related]

  • 25. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
    Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW.
    Neoplasma; 2005 Sep 15; 52(3):219-24. PubMed ID: 15875083
    [Abstract] [Full Text] [Related]

  • 26. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F, Fan D, Qi J, Zhu H, Zhou Y, Yang C, Zhu Z, Xiong D.
    Life Sci; 2008 Sep 26; 83(13-14):496-501. PubMed ID: 18725232
    [Abstract] [Full Text] [Related]

  • 27. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.
    Oncol Rep; 2012 Jun 26; 27(6):1703-9. PubMed ID: 22426819
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.
    Mol Cancer Res; 2008 Aug 26; 6(8):1347-55. PubMed ID: 18708366
    [Abstract] [Full Text] [Related]

  • 30. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
    Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T.
    Mol Cancer Ther; 2003 Jan 26; 2(1):105-12. PubMed ID: 12533678
    [Abstract] [Full Text] [Related]

  • 31. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
    Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD.
    Cancer Res; 2006 May 15; 66(10):5007-11. PubMed ID: 16707421
    [Abstract] [Full Text] [Related]

  • 32. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
    Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y.
    Mol Pharmacol; 2003 Sep 15; 64(3):610-8. PubMed ID: 12920197
    [Abstract] [Full Text] [Related]

  • 33. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
    Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J.
    Cancer Sci; 2005 Aug 15; 96(8):457-65. PubMed ID: 16108826
    [Abstract] [Full Text] [Related]

  • 34. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells.
    Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD, Mao Q.
    Am J Physiol Endocrinol Metab; 2006 May 15; 290(5):E798-807. PubMed ID: 16352672
    [Abstract] [Full Text] [Related]

  • 35. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 15; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP.
    Anticancer Res; 2003 Dec 15; 23(2B):1455-60. PubMed ID: 12820409
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.